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Abstract: This series of experiments attempted to characterize the abilities of 
stem cells derived from bone marrow and adipose tissue to integrate into the 







Interest in the therapeutic possibilities of stem cells has led to preliminary studies involving stem 
cell use in the treatment of inner ear disorders.  Deafness brought on by hair cell or spiral 
ganglion loss is permanent in mammals.  The regenerative properties of stem cells suggest that 
these cells could be introduced to the damaged inner ear to possibly restore function.  This study 
used mesenchymal stem cells from the bone marrow and omentum of mice.  In some cases cells 
were transfected with a plasmid containing GFP and Math-1 as well as with hair cell 
intercellular proteins.  Donor cells were injected into chicken embryos at embryonic day 3 (E3) 
Hamburger and Hamilton’s (1951) stages 14 - 18.  Inner ear portions of the embryo were 
dissected out and fixed at 1 - 4 day intervals.  Once frozen, these blocks were sectioned and 
processed for hair cell, neuronal, and mesenchymal cell markers with immunohistochemical 
staining.  Results show that injected cells were present in the developing otocyst and survived 
until day E7.  Some cells integrated into the periotic mesenchyme, but none expressed any hair 
cell markers.  It can be concluded that this injection protocol is effective in delivering enriched 
stem cells to the inner ear, but the fate of these cells remains undetermined.  Further evaluation 
of the molecular properties of these injected cells and more accurate phenotyping may help to 
better characterize the possible transdifferentiation, integration, and therapeutic use of stem cells 
in the inner ear. 
 
Introduction 
Permanent sensorineural deafness occurs as a result of loss of hair cells in the cochlea or of their 
primary afferents the spiral ganglia neurons, or due to damage along the auditory nerve.  The 
mechanisms of damage include: genetic mutation, autoimmune or infectious diseases, chemical 
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ototoxic agents, mechanical acoustic trauma, or metabolic oxidative stress.  Therapies involving 
the use of hearing aids or cochlear implants provide benefit to most people with hearing loss, but 
full restoration of “normal hearing” is limited by the anatomy and physiology of the impaired 
system.   
 Stem cell therapies aim to restore “normal” cellular function by inducing undifferentiated 
cells to a specific fate needed by the recipient.  In the case of hearing loss, stem cells have the 
potential to differentiate into new hair cells, neurons, and supporting cells.  This technology is 
still in its early stages.  Several recent studies have explored the ability of stem cells to adopt a 
neural fate in vitro.  Fewer studies have demonstrated in vivo or inner ear applications; however, 
there are still many studies showing that stem cells from a variety of sources can differentiate 
into mature cells expressing certain genes, labeling for target cell markers, or even functioning in 
the inner ear.  Variables in these studies have yet to indicate an ideal animal model, cell source, 
or protocol based on survival rate and differentiation ability of the stem cells; therefore, a review 
of the literature can serve only to discover new combinations of variables yet to be attempted to 
further illustrate the role of stem cells as a therapy for inner ear cell loss. 
Sources of Stem Cells  
“A stem cell is a cell that gives rise to progeny with more than one differentiated phenotype and 
that may be greatly expanded in an undifferentiated form” (Pittenger and Marshak 2001). 
Embryonic Stem Cells (ESCs) are cells derived from the inner cell mass of the blastocyst (Smith 
2001).  Some articles claim that these cells are ideal for stem cell therapies because they are 
“totipotent,” able to differentiate into any cell type.  Most authors suggest that “pluripotent” is a 
more appropriate term.  ESCs to give rise to cells of all three germ layers and to germ cells, but 
they cannot generate a blastocyst (Smith 2001).  They are useful for somatic cell nuclear transfer 
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cloning and for somatic cell regeneration.  As pluripotent cells, ESCs are an attractive source for 
research.  In theory, ESCs could be expanded and partially differentiated into any desired cell 
type in vitro and then injected or grafted in vivo.  Even undifferentiated ESCs can differentiate in 
vivo by responding to developing embryonic environmental cues or damage-induced trophic 
factors in the adult.  Drawbacks to ESC use include the teratogenic (tumor forming) ability of 
these cells and the current restricted use of human embryonic stem cells due to legal and ethical 
concerns (Parker and Cotanche 2004). 
 In vitro studies using ESCs attempt to characterize the ability and efficacy of certain 
factors to induce these cells into a neuronal fate.  For example, Matsumoto et al (2005) 
demonstrated the ability of ESCs enriched with SDIA (PA6 stromal cells) to differentiate into 
TuJ1-expressing neuron-like cells after seven days of co-culture with the auditory epithelia of 
neonatal mice.  In vitro these cells had neurites that elongated toward the basolateral surface of 
the hair cells in the cochlear explants.  In addition, the ESCs expressed synaptophysin near the 
hair cells indicating the presence of synaptic vesicles at the neurite terminals and the ability for 
these new neurons to be functional.   
 To show ESC interactions in the vestibular epithelium, Kim et al (2005) used the same 
protocol with neonatal mouse utricles instead of auditory epithelia.  Results indicated that ESCs 
had invaded the vestibular epithelium and labeled for TuJ1.  To further define the characteristics 
of these cells, the authors also labeled for NR1 (a Scarpa’s ganglion post-synaptic marker).  
Expression of certain neurotransmitter markers (like NR1, GABA, glutamate, cholinergic and 
catecholaminergic markers) indicated that these ESCs fully differentiated into a variety of 
desired inner ear neuronal subclasses.  It is particularly interesting that these ESCs mostly 
expressed markers for glutamate—the afferent neuron sensory transduction neurotransmitter.  In 
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addition, these cells had neurites that projected to the basolateral edge of the vestibular hair cells 
and expressed synaptophysin, demonstrating that they are functional glutaminergic neurons.   
 In vivo studies demonstrate the ability of ESCs to use host cues for differentiation, 
integration, and function.  ESCs injected into the modiolus and auditory nerve can 
integrate/engraft and differentiate into functional neurons.  Okano et al (2005) reported that 
ESCs can preserve function both in normal hearing and in kanamycin-deafened guinea pigs 
when injected into the modiolus through the scala tympani.  These mouse ESCs enriched with 
retinoic acid (RA) and SDIA were able to survive for three weeks.  These cells exhibited 
neuronal marker TuJ1 (labeling for β III Tubulin) and projected neurites all the way to the brain 
stem.  Auditory brainstem responses (ABR) indicate that the thresholds of the injected group—
although not as good as normals—still showed improvements in ABR thresholds compared to 
damaged ears without stem cell treatment.   
 Similarly, Hu et al (2005a) injected ESCs directly into the auditory nerve fibers through 
the modiolus.  These cells expressed GFAP (for glial cells) and neurofilament (for neural cells).  
By three weeks post-injection the cells could be found in the basal turn of the cochlea and in the 
internal auditory meatus.  By six weeks, the ESCs had begun to migrate centrally; so that by nine 
weeks ESCs were located in the brain stem near the ventral cochlear nucleus.   
 Sakamoto et al (2004) explored the use of ESCs in neomycin-damaged posterior 
semicircular canals of adult mice.  Donor cells were either undifferentiated or partially- 
differentiated into a neuronal cell fate (by co-culture with SDIA PA6 stromal cells).   At four 
weeks post-injection, few injected cells were present in the scala media of the cochlea and none 
of these cells expressed the hair cell marker myosin VIIA.  Most of the injected cells were in the 
vestibular areas expressing β III tubulin.  There was no expression of a mesodermal marker in 
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any of the injected cells, indicating that these ESCs had undergone differentiation into 
ectodermal neurons.   
 Using both in vitro and in vivo methods, Li et al (2003b) demonstrated that ESCs could 
differentiate into hair cells, in addition to neurons and glial cells.  In vitro, hair cells were 
generated via stepwise differentiation of ESCs.  Using RT-PCR (to characterize gene expression) 
and immunohistochemical markers at different stages of development, these authors showed that 
ESCs respond to an enriched medium of epidermal growth factor (EGF) and basic fibroblast 
growth factor (bFGF) and develop into clones expressing neural progenitor cell markers like 
nestin, pax2 and BMP7.  When the growth factors were removed from the media, the cells no 
longer expressed the progenitor genes.  They had differentiated even further into cells co-
labeling with Math-1 and either myosin VIIA or Brn3.1 in ways similar to developing hair cells.  
Finally, these differentiated cells were injected into the developing chick inner ear at stage 16 - 
17.  At 16 hours post-injection, some of the ESCs had already integrated into the host epithelium 
at the site of damage from the injection.  Others integrated elsewhere into the supporting cell 
layer.  By three days post-injection, ESCs that had integrated into the epithelium had 
morphology similar to the mature hair cells of the surrounding chick host.  In the vestibular 
epithelium of the utricle, injected ESCs labeled with espin for F-actin rich stereocilia.  These 
data suggest that embryonic stem cells injected into the developing inner ear of the chick are able 
to integrate into the epithelium and differentiate into hair cells; however it was not determined 
whether these hair cells were functional. 
 In summary, ESCs can integrate into embryonic or damaged adult sensory epithelia in the 
ear.  Also, ESCs can differentiate into neural cell types such as hair cells, supporting cells, glial 
cells, and neurons of several subclasses. 
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Neural Stem Cells (NSCs) are neural cells from the dorsal telencephalon, the dorsal root ganglia 
(DRG), the lateral wall of the lateral ventricle, or the hippocampus that have stem cell properties.  
NSCs are multipotent and expand in culture without undergoing further differentiation.  NSCs 
are different than neural progenitors created via neural induction of ESCs.  Unlike ESCs, NSCs 
can be derived from adult, neonatal, or embryonic cells.  Also, NSCs have a more limited self-
renewing ability and are more restricted in their ability to differentiate into other cell types 
(Panicker and Rao 2001).  Despite this, NSCs seem to be a more-natural choice when 
considering stem cell inner ear therapy because both inner ear cells and NSCs are derived from 
the ectoderm and neural progenitors.  Also, cells of the otocyst are influenced by neural tube 
factors during development (Parker and Cotanche 2004), making it likely that inner ear cells and 
injected NSCs may continue to be receptive to neural cell signals at later stages too.  Several in 
vivo studies pertaining to the inner ear can be found in the published literature on NSCs. 
 Tamura et al (2004) used NSCs from the dorsal telencephalon of fetal mice.  These cells 
still expressed the neural progenitor nestin, but had yet to express TuJ1 or GFAP.  Two weeks 
after injection into the modiolus of cisplatin-damaged adult mice, NSCs had integrated 
throughout the inner ear.  Donor cells robustly survived in the basal and apical scala tympani and 
in the modiolus.  Among the spiral ganglia, injected NSCs predominantly expressed GFAP, 
indicating a glial cell fate.  Out of all the integrated NSCs in the osseous spiral lamina, only 
~10% expressed TuJ1.  This suggests a limited potential for NSCs to differentiate into spiral 
ganglion neurons.  To verify any functional benefit of these cells, the authors admit that these 
NSCs would have to show more extensive neural outgrowth to be therapeutically useful. 
 In a study by Tateya et al (2003), fetal mouse dorsal telencephalon NSCs expressing 
nestin, but not MAP2 or GFAP were injected into the second cochlear turn of adult mice 
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damaged with neomycin.  After 25 days, NSCs had integrated into the utricle and the ampullar 
cristae and had labeled with myosin VIIA.  In cochlear structures, NSCs in the perilymph spaces 
of the scala tympani expressed GFAP and MAP 2.  These cells did not integrate into the 
epithelium, but they did adopt neuronal and glial cell fates.  Data from these two comparable 
studies demonstrate that fetal dorsal telencephalon NSCs can differentiate into vestibular hair 
cells, spiral ganglia, or glial cells by 4 weeks post-injection.  These multipotent dorsal 
telencephalon cells are useful for therapy in the inner ear by restoring an array of cell types when 
damaged with cisplatin or neomycin. 
 Regala et al (2005) injected fetal DRGs or adult lateral wall of lateral ventricle rat NSCs 
into adult rats damaged only mechanically by the injection.  At four weeks post injection NSCs 
were located along the proximal vestibulocochlear nerve extending into the brainstem as labeled 
with Thy-1.2, a neuronal marker.  The fetal DRGs had fewer cells surviving at four weeks than at 
two weeks; however, the adult lateral ventricle NSCs were greater in number at four weeks than 
at two weeks.  The authors conclude that since more spiral ganglia would be more useable for 
therapy, the proliferating adult ventricle NSCs are preferred over the fetal DRGs that diminish 
over time.  
 Hu et al (2005a) grafted fetal mouse DRGs into transected auditory ganglia damaged by 
neomycin.  These NSCs expressed neurofilament and survived until nine weeks post-injection.  
Even though NSCs were injected at the basal turn of the cochlea, neurites from these cells 
migrated from the modiolus toward the brain stem during a 3 – 9 week period.  However, most 
NSCs remained near the injection/grafting site.  Compared to the pluripotent ESCs also used in 
this study, NSCs demonstrated less differentiation into fewer cell types and less migration 
toward the brainstem.  These results are to be expected from the less multipotent NSCs.   
 8
Randazzo 
 Hu et al (2005b) attempted another study using NSCs from the lateral wall of the lateral 
ventricles of adult mice.  After enrichment with EGF and bFGF and transfection with GFP and 
neurogenin, these cells were injected into the scala tympani at the basal turn of undamaged 
cochleae or cochleae damaged with neomycin.  By two weeks post-injection, NSCs attached to 
the osseous Rosenthal canal integrating among the auditory nerve fibers.  These NSCs were 
close to the spiral ganglion neurons and expressed GFAP, suggesting a glial cell fate.  NSCs 
were also in the lumen of the scalae tympani and vestibuli from base to apex.  This confirms the 
migration ability of NSCs noted in other studies.  Only in deafened animals did these NSCs 
express β III tubulin and GFAP; however some TuJ1 expression was noted in normal hearing 
animals injected with neurogenin-transfected NSCs.  None of the injected cells in any of the 
animals express myosin VIIA.  These results show that lateral ventricle NSCs are multipotent—
able to differentiate into several cell types throughout the inner ear, but not into hair cells.  These 
data suggest that compared to normal cochleae, inner ears damaged with neomycin had more 
NSC integration and differentiation; but these data cannot determine if the injected cells were in 
fact functional. 
 Finally, Ito et al (2001) used yet another NSC source: adult rat hippocampal cells 
enriched with N2 and FGF.  They injected these cells into the cochleae of presumably normally 
developing neonatal rats with no predisposition to hearing loss.  At two weeks post-injection, 
NSC spheres merely lined the wall of the cochlear cavity.  By four weeks, surviving NSCs had 
integrated into the organ of Corti among the inner and outer hair cells.  These cells expressed 
phalloidin indicating presence of hair cell morphology.  According to the authors, NSCs also 
differentiated into astrocytes and oligodendrocytes in addition to hair cells, illustrating the 
multipotent ability of these hippocampal NSCs.   
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 No studies were found that used NSCs applied to the developing chick inner ear.  
However, Fontaine-Pérus et al (1995, 1997) grafted embryonic mouse NSCs into embryonic 
chicks’ somites at stages similar to the time period of the developing otocyst (day E2 – E8).  
NSCs managed to integrate into all three germal layers of the chick and to develop similarly to 
the neighboring host cells by responding to environmental cues. 
 In summary, NSCs have a somewhat diminished capacity (compared to ESCs) to 
differentiate in vivo into hair cells, neurons, and glial cells somewhere between 3 - 4 weeks post-
injection.  Results indicate that NSCs can proliferate and integrate into both normal and damaged 
inner ears of both adult and post-natal mammals, making them a useful stem cell source for inner 
ear therapy.   
Mesenchymal Stem Cells are derived from bone marrow, umbilical cord blood, adipose tissue, 
and muscle (Krabbe et al 2005).  Subclasses of mesenchymal stem cells like Hematopoietic Stem 
Cells (HSCs), Marrow Stromal Cells (MSCs), and Adipose-derived Stem Cells (ASCs) may 
serve as therapeutic cell sources for use in the inner ear.  HSCs are rare, multipotent, self 
renewing cells derived from mesoderm.  Everyday, HSCs reconstitute blood cells in the bone 
marrow by differentiating into progenitors for erythrocytes, lymphocytes, macrophages, 
platelets, natural killer cells, osteoclasts etc. in the process of hematopoiesis.  Bone marrow 
transplant (BMT), a therapy for blood disorders, utilizes the ability of HSCs to reconstitute all 
blood cells for the host (Orkin 2001).  MSCs are derived from the bone marrow stroma that 
supports HSC hematopoiesis.  Marrow stromal cells constitute a complex mixture of 
uncharacterized cells.  The stem cells in the stroma regenerate tissues such as bone, tendons, 
skeletal and cardiac muscle (Pittenger and Marshak 2001).  Both HSCs and MSCs can be 
extracted from the iliac crest of the pelvis, the tibia and femur, and the thoracic and lumbar spine.  
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Finally, ASCs are stem cells found in fat tissue.  These self-renewing, multipotent cells are as 
accessible and replenishable as HSCs and MSCs, making mesenchymal stem cells excellent 
sources for stem cell therapy. 
 In order for these cells to be useful source for inner ear cell therapy, mesenchymal cells 
must demonstrate the ability to transdifferentiate from their mesoderm cellular fate into a neural 
cell fate.  According to Krabbe et al (2005), transdifferentiation describes the “plastic ability of 
an adult stem cell to differentiate into cell lineages of the tissues different from the lineage in 
which the somatic cell resides—even into cells originating from other germ layers.”  Mesoderm-
derived stem cells would need to be as pluripotent as ESCs to undergo transdifferentiation into 
ectoderm cell types like hair cells or spiral ganglia.  To test the ability of mesenchymal stem cells 
to transdifferentiate into inner ear ectoderm-derived cells, both MSCs and ASCs were used in 
our experiment. 
 There are several studies that explore the neural differentiation of all types of 
mesenchymal stem cells into neural structures of the eye, spinal cord, and hippocampus.  For 
thorough reviews including both in vitro and in vivo studies see Ortiz-Gonzalez at al (2004) and 
Lu & Tuszynski (2005).  The few published studies that pertain to the inner ear, to the chick, and 
to omental cells are described below.   
 One way of using mesenchymal cells in the ear is through BMT: replacement of all of the 
host blood cells with donor stem cells after complete irradiation.  Studies of animal models 
disposed to autoimmune inner ear disease and presbycusis, illustrate that HSC and MSC 
transplants can restore functional hearing.  Iwai et al (2005) and Lee et al (2000) used the 
auditory brainstem response (ABR) at 24 weeks post-transplantation to verify that experimental 
animals had thresholds similar to normals and much better than control deafened animals that did 
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not receive BMT.  Iwai et al (2001) also showed that BMT can stop the loss of hair cells and 
spiral ganglia that occurs with presbycusis.  These authors attribute the therapeutic ability of 
BMT in the inner ear to the lack of IgG deposits in the stria vascularis in the injected mice.  This, 
in combination with macrophage release of neuron growth factor, helps to preserve hearing in 
these BMT models.  However, the destruction of all host blood cells is not a useful strategy for 
patients with hearing loss.  In addition, other types of hearing loss not caused by a faulty immune 
response may not be responsive to this therapy.  In our study, a more-conventional injection 
protocol was used to localize the mesenchymal stem cell therapy to only the inner ear.   
 Naito et al (2004) described the autologous injection of enriched MSCs into the inner ears 
of adult chinchillas damaged with gentamycin.  At three weeks post-injection, the MSCs were 
located in the scalae vestibuli and tympani, the spiral ligament, and the stria vascularis of all 
cochlear turns.  Most notably, some cells were found in the modiolus.  The lack of injected cells 
in the scala media was attributed to the high potassium ion concentration of the surrounding 
endolymph.  The authors suggest that the microenvironment of the scala media may not be a 
suitable for injected MSCs.  The MSCs that did integrate expressed neural markers NF200 and 
GFAP.  The authors state that these cells could have some use clinically; but compared to other 
studies in their lab with NSCs, the MSCs have less differentiation potential. 
 The only other use of MSCs in inner ear comes from an in vitro study by Kondo et al 
(2005).  First these authors isolated MSCs and cultured them in an enriched media containing 
retinoic acid and sonic hedgehog.  Only when combined did these two agents cause the MSCs to 
become neural progenitors expressing nestin.  Next, the media was supplemented with FGF 
causing the flat MSCs to change morphology into more round cell bodies with neurite-like 
processes.  These cells were post-mitotic and had differentiated into neural cells.  Then, the 
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authors grafted these partially-differentiated MSCs into an embryonic mouse organ of Corti.  
After one week of co-culture, the MSCs expressed sensory cell markers in both the vestibular 
and cochlear ganglia, in the trigeminal ganglia, and in the DRG.  The cells in the vestibulo-
cochlear ganglia labeled positive for TuJ1, calretinin, NeuN, Gata-3, NF and MAP 2.  In most 
cells, the expression profile was similar to that of glutamatergic neurons, the type of afferent 
neurons in the ear. 
 Bone marrow hematopoietic and stromal stem cells have been used in experiments 
describing neural development of the embryonic chick, but not specifically in the ear.  In one 
study by Pochampally et al (2004), MSCs were grafted into stage 12 – 13 (~ day E2) chicks at a 
damage site along the somite region of the embryo.  Four days later, engrafted cells had migrated 
to and integrated into the heart, liver, brain, and spinal cord.  The MSCs only comprised a small 
portion of the total number of cells indicating that even though MSCs can expand and develop in 
to all three germal layers; they do so much more slowly and less effectively than the host chick 
somites.  These authors did not detect any multinuclear cells, suggesting a lack of cell fusion 
(mouse/chick hybridization at the cellular level).  Sigurjonsson et al (2005) injected CD34 
positive human HSCs into the lumbar spinal cord of stage 15 – 16 embryonic chicks.  Nine days 
later, most of the embryos showed some integration of HSCs into neural tissue.  Particularly in 
the DRG, HSCs expressed neural markers MAP 2, NeuN, GABA and synaptotagmin and 
stopped expressing the hematopoietic cell marker CD34.  Also, voltage sensitive action 
potentials could be measured from these HSC-derived neurons using whole-cell recordings.  
These findings suggest that a mouse/chick chimera can illustrate the transdifferentiation ability 
of mesenchymal stem cells into functional neural cells in vivo.   
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 Stem cells have also been found to exist in the adipose tissue.  Like all other stem cells 
described above, these ASCs can transdifferentiate in vitro into neural cells.  Safford et al (2002) 
isolated ASCs from human fat readily-available from easily-accessible, discarded liposuction 
waste.  The ASCs were induced along a neural cell fate with the help of butylated 
hydroxyanisole (BHA).  After one day of culture, ASCs expressed the neural progenitor, nestin.  
With further enrichment by bFGF and EGF, the neural progenitors adopted a more mature 
neuron-like morphology.  ASCs derived-neural cells did not survive longer than 2 weeks in 
culture.  Despite their ability to transdifferentiate, the culturing of ASCs must be improved to 
prolong survival if they will prove to be a useful source for inner ear stem cell treatment.  An 
unpublished series of experiments from Shin et al utilize ASCs derived from the stromal 
mesenchymal cells of the adipose tissue in the adult mouse omentum.  Once expanded in culture, 
these cells expressed CD34, CD29, GAPDH, vimentin, and FSP1 similarly to ESCs.  Studies are 
underway to determine the further neural differentiation abilities of these ASCs. 
 In summary, with the functional recovery of hearing in animals transplanted with stem 
cells via BMT already established, further research is needed to fully understand the 
transdifferentiation abilities of all types of mesenchymal stem cells and their possible uses to 
repopulate lost neural cells in the inner ear. 
Inner Ear Stem Cells (IESCs) are inner ear supporting cells that maintain the ability to self-
renew in culture.  To be classified as a stem cell, these IESCs must also be multipotent—able to 
differentiate into cell types other than those inherent to the corresponding somatic cells.  Li et al 
(2003a) set out to find and characterize these IESCs.  First, the utricular maculae and the 
underlying stroma were removed from adult mice.  The cells were isolated and eventually self-
renewed by the formation of spheres—all without evidence of cell fusion.  In vitro, these IESCs 
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could be induced along a mesodermal cell fate by co-culture with myogenic cells.  The IESCs 
then further differentiated into myotube-forming cells that expressed muscle cell markers myosin 
heavy chain and MyoD.  In vivo, IESCs were grafted into the amnionic cavity of stage 4 chick 
embryos.  Early implantation allowed the IESCs to distribute during gastrulation into all three 
germ layers.  Two days later, IESCs had integrated into developing mesodermal cells of the 
kidney and heart, endodermal liver cells, and ectodermal cells in the skin.  Just like the host cells, 
these multipotent IESCs were able to respond to the local environmental cues and differentiate 
into a variety of cells. 
 Once Li et al defined these IESCs as true stem cells, they then determined the potential of 
these cells to differentiate into inner ear cell types in vitro and in vivo.  Isolated IESC cultures 
were enriched in a medium to induce nestin expression.  Most of the cells advanced out of the 
self-renewing cell cycle and began to differentiate into neural progenitors.  These partially-
differentiated cells also expressed inner ear development markers Pax-2, BMP-4 and BMP-7.  
The authors then allowed more time for further differentiation to occur.  Two weeks later, some 
IESCs had differentiated into hair cells indicated by myosin VIIA and Brn3.1 expression.  Some 
cells co-labeled for myosin VIIA and espin markers, indicating the presence of F-actin 
stereocilia.  Since this expression profile of markers is exclusive to inner ear hair cells, these 
experiments can conclude that the IESCs are able to differentiate into mature hair cells.  
Differential staining showed that supporting cells expressing pan-cytokeratin could also be 
derived from these IESCs.  In vivo, nestin-expressing IESCs were injected into the developing 
chick otocyst at stages 16 - 17.  Five days post-injection, these cells expressed myosin VIIA at 
the same time and in the same locations as the surrounding chick hair cells.  These data show 
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that IESCs are capable of integrating into the sensory epithelium and of receiving environmental 
cues from the chick to differentiate into hair cells.     
 Kojima et al (2004) injected cells from the developing otocyst of rats at embryonic day 
12 into postnatal rats that had been exposed to damaging levels of noise.  One month after 
injection into the middle turn of the cochlea, IESCs had integrated along the injection tract to the 
cochlea, the lateral walls, the modiolus, and the scalae tympani and vestibuli.  IESCs either lined 
up along the inner lumen of the perilymph-filled spaces or accumulated into a mass of cells in 
these areas.  A few cells had migrated to the basilar membrane areas where hair cells and 
Claudius cells had died from acoustic over-stimulation.  These IESCs only integrated into the 
supporting cell layers, adopting supporting cell morphology.  No IESCs integrated into the organ 
of Corti to become hair cells.   
 IESCs may be involved in hair cell regeneration.  In non-mammals, some supporting 
cells receive signals from the environment after damage.  These cells then re-enter the cell cycle 
to asymmetrically divide into a new hair cell and another supporting cell.  In about two weeks, 
new, mature hair cells re-populate the epithelium by this mechanism.  These re-differentiated 
cells innervate with existing neurons to restore function.  Mammals have demonstrated limited 
hair cell regeneration in the vestibular epithelium, but are unable to regenerate hair cells in the 
cochlea by this mechanism (Parker and Cotanche 2004).  Whether these supporting cells are 
multipotent and stem-cell-like has yet to be determined.  Nevertheless, the existence of IESCs 
may prove to be the best therapeutic option for inner ear stem cell therapy.  What is lost in 
pluripotency may be gained by fewer intermediary steps needed for differentiation.  These cells 
may only need one master switch to be enabled—like Math-1, and possibly new hair cells could 
be generated.   
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Stem Cell Enrichment 
 Stem cells are pluripotent; but with hearing loss, only a few—not many—cell types are 
needed for therapy.  In order to coax stem cells to differentiate along the desired neural fate 
toward hair cells and spiral ganglia, cultures of stem cells can be supplemented or enriched with 
a variety of factors.   
 Stem cells of all types can use an array of environmental factors present in the host or in 
the culture medium to adopt inner ear cell fates.  Some studies use growth factors like insulin-
like growth factor (IGF-1), glial-cell derived neurotrophic factor (GDNF), basic fibroblast 
growth factor (bFGF), and most successfully, epidermal growth factor (EGF).  EGF either alone 
or in combination with other agents begins the partial differentiation of ESCs into neural 
progenitors expressing nestin (Li et al 2003b).  EGF also induces sphere forming and 
proliferation in NSCs (Tamura et al 2004).  EGF together with IGF is most effective in IESC 
neural induction (Li et al 2003a).  Even partially differentiated MSCs respond to bFGF in culture 
and go on to adopt more mature neural cell types.  Aside from growth factors, other agents that 
normally take part in inner ear development, like retinoic acid and sonic hedgehog, can be 
introduced to stem cells in culture media to aid in neural induction prior to injection (Kondo et al 
2005).   
 Other enrichment protocols involve co-culture with either stromal cells or neuronal cells.  
A process called stromal cell-derived inducing activity (SDIA) describes the ability of PA6 
stromal cells to induce ESCs toward a peripheral or sensory neuronal fate by differentiation into 
neural crest cells.  Many of the ESC studies discussed earlier used SDIA to induce nestin 
expression prior to stem cell injection (Okano et al 2005, Kim et al 2005, Matsumoto et al 2005, 
Sakamoto et al 2005).  ESCs can also be co-cultured with embryonic DRGs for neural induction.  
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Hu et al (2004, 2005a) compared outcomes from an enriched group of ESCs to the outcomes of 
ESCs without enrichment.  Whether or not ESCs were enriched with the co-graft, both groups of 
cells integrated into the host animal and expressed TuJ1 as early as 2 weeks post-injection.  
Enriched ESCs survived longer, expressed more TuJ1, and had neurite projections reaching 
further towards the modiolus than the ESCs without co-culture. 
 In addition to environmental factors and co-culture, donor stem cells can be transfected 
with certain genes to influence cell fates.  Plasmids coding for a promoter and the desired genes 
can enter the cells via viral vector infection or electroporation.  In studies of the ear, a hair cell 
gene Math-1 and a neural gene, neurogenin have been transfected into cells of the inner ear with 
the hopes of creating these neural cell types.   
 Studies in Drosophila have indicated that the basic helix-loop-helix transcription factor, 
atonal is necessary for hair cell development.  Homologs of atonal, Math-1 (mouse) and Hath-1 
(human), influence nestin-expressing neural progenitor cells to differentiate into hair cells.  By 
acting as a “master switch” Math-1-expressing cells develop into hair cells in the appropriate 
culture medium.  For example, dissociated embryonic otocyst cells expressing Math-1 mature 
into hair cells with a combination of EGF and peri-otic mesenchymal cells that act as a 
supportive layer (Doetzlhofer et al 2004).  These otocyst cells eventually label for myosin VIIA, 
calretinin, and phalloidin, indicating that Math-1-expressing cells develop into mature hair cells 
with calcium channels and stereocilia.  However, without Math-1 neural progenitors do not 
become hair cells.  In vitro experiments by Chen et al (2002) illustrated that embryonic mouse 
cochlear explants first transfected with a Math-1 enhancer could express Math-1 upon exiting the 
cell cycle and could differentiate into cells labeling for myosin VIIA.  But in the same 
 18
Randazzo 
conditions, transgenic Math-1-null mice did not express any Math-1 or label for myosin VIIA 
indicating a lack of hair cell formation due to the lack of the Math-1 gene.   
 Zheng and Gao (2000) reported that postnatal rat cochlear and utricular explants infected 
with a Math-1 plasmid generated extra hair cells.  Six days after infection, numerous new hair 
cells were located in the greater epithelial ridge and expressed myosin VIIA.  Results with the 
utricular explants suggest that Math-1 facilitates hair cell regeneration by supporting cell re-
differentiation.  These authors conclude that Math-1 is necessary for hair cell differentiation in 
both cochlear and vestibular structures.  Shou et al (2003) published similar findings with Hath-1 
expression in postnatal rat cochlear explants.  Although, none of the existing spiral ganglia or 
hair cells labeled for Hath-1, supporting cells in the greater epithelial ridge and in the lateral 
organ of Corti (lesser epithelial ridge) were infected with Hath-1 via electroporation and six days 
later these cells labeled for myosin VIIA.    These authors attempted another similar experiment 
with mature utricular explants damaged with aminoglycosides.  In these mature utricles, none of 
the Hath-1-infected cells labeled for myosin VIIA at 3 days post-infection; but by 7 – 18 days 
following infection, nearly all of the Hath-1-expressing cells also labeled for myosin VIIA.  
These studies confirm the need for expression of an atonal homolog for hair cell differentiation 
in the developing cochlea and utricle. 
 Kawamoto et al (2003) demonstrated that in vivo, Math-1 transfects supporting, Hensen 
cells and greater epithelial ridge inner sulcus cells when introduced to the mature inner ear of the 
guinea pig.  One to three months following injection, these supporting cells had changed their 
morphology to resemble a pear-shaped hair cell with stereocilia visible with scanning electron 
microscopy.  The authors point out that the number of transfected cells was few and that these 
new, immature hair cells were ectopically placed in unpredictable locations.  Despite these 
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possible detriments to a clinical use for Math-1 gene therapy, the authors also report (by labeling 
with neurofilament) that axons extended from the organ of Corti all the way over to the ectopic 
cells.  These results are exciting because if new hair cells are to be made via gene or stem cell 
therapies, they still must prove functional in vivo.  The possibility of synapses with spiral ganglia 
is a good first step.   
 Li et al (2003b) performed both in vitro and in vivo experiments showing that Math-1 is 
also required for stem cells to differentiate into hair cells.  Math-1 was expressed only after the 
IESC spheres exited the cell cycle.  These cells then became neural progenitors expressing 
nestin.  After 14 days in culture, all IESCs labeling for Math-1 also expressed myosin VIIA, 
suggesting a hair cell fate.  When undifferentiated IESCs were injected into embryonic chick 
utricle sensory epithelium in vivo, Math-1 was expressed only by cells that eventually became 
hair cells, and was not expressed by any injected cells that became supporting cells. 
 Donor cells should also be labeled in order to discriminate between donor and host cells 
in both in vitro and in vivo studies.  Oftentimes the stem cells are transfected with genes like lacZ 
that labels with β-gal staining or with green fluorescent protein (GFP) for easy identification of 
injected cells. 
 In our experiments with omental cells, we injected hair cell proteins of unknown 
composition into the isolated ASCs.  The effect of these proteins was also unknown, but perhaps 
they served as a hair cell induction mechanism or as enrichment proteins.  To direct these ASCs 
toward more-desirable cell fates, the cells were transfected with neurogenin (for neurons) or 
Math-1 (for hair cells).  To more clearly identify the injected cells from the surrounding host 





 In choosing an experimental model, it seems logical to use a clinically analogous 
mammalian paradigm: adult hosts subjected to damage simulating an acquired deafness or 
postnatal hosts with a genetic mutation approximating a congenital hearing loss.  In the studies 
already mentioned, adult guinea pigs, mice, and chinchillas were damaged with noise, cisplatin, 
loop diuretics, aminoglycosides, or mechanical damage.  Sometimes host animals included 
embryonic chicks and postnatal rats, but rarely have researchers used a congenital deafness 
model (i.e. “knocking out” normal inner ear development genes or coding for one of the known 
deafness gene mutations). 
 Sometimes, a clinically applicable design may not yield a strong enough result and no 
firm conclusions can be drawn from the data.  For example, Sakamoto et al (2004) used two 
different protocols with two different hosts.  As already discussed, undifferentiated rat ESCs 
were injected into the inner ears of adult mice.  Injected ESCs were primarily located in the 
vestibular area four weeks after implantation.  These cells labeled for neural markers (NCAM 
and β III tubulin), but none labeled for myosin VIIA.  As hair cell differentiation was the goal of 
this experiment, the authors tried to produce a stronger result by using a chick model instead.  
Rat ESCs enriched with SDIA and BMP-4 were injected into the chick otocyst at stage 10 – 17.  
By two days post-injection (approximately day E5), cells were located in the lumen of the 
otocyst and in the mesenchyme near the dorsal edge of the otocyst and in the delaminating 
vestibulo-acoustic ganglia, but none of these cells labeled for myosin VIIA either.  Even though 
neural induction mechanisms were assumed to be stronger in the developing chick than in the 
adult mouse, integration and differentiation were as limited in the chick as in the mouse for this 
experiment.   
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 Embryonic chicks have been useful for the study of vertebrate developmental physiology.  
Hamburger and Hamilton (1951) staged the chick embryo by appearance of morphological 
features.  Knowlton (1967) described inner ear development of sensory and neural cochlear and 
vestibular structures.  Additional resources for inner ear development include Bissonnette and 
Fekete (1996) and Lang and Fekete (2001).  Also, chicks can effectively serve as host animals in 
implantation and grafting experiments involving stem cells and the inner ear.  As previously 
reviewed Li et al (2003a, 2003b) used chick inner ear explants in their ESC and IESC 
experiments.  Furthermore, neural induction studies by Fontaine-Pérus (1995, 1997), 
Pochampally et al (2004), and Sigurjonsson et al (2005) all used the embryonic chick host model 
with success, although not within the inner ear.  Opposed to a mammalian model, we chose to 
use embryonic chicks as host animals for our mesenchymal stem cell injection experiments. 
Injury to Host 
 As reviewed previously, adult host animals are often damaged with noise, cisplatin, loop 
diuretics, or aminoglycosides (neomycin or kanamycin).  Sometimes, no damage is caused—
except by the actual injection of the stem cells into the inner ear structures.  In a comparison of 
deafened and normal ears, Okano et al (2005) found no significant differences in the number of 
surviving injected ESCs between the two groups.  Also, this study did not report any additional 
integration or expression with the deafened group over the normal hearing group.   
 Similarly, Hu et al (2005a) showed that for animals exposed to kanamycin damage, there 
was no difference when compared to normals for longevity of ESC survival or for amount of 
TuJ1 expression.  But in another experiment (Hu et al 2005b), treatment of the cochlea with 
neomycin did affect survival and expression of injected NSCs at two weeks post injection.  The 
number of animals showing NSC survival was about 40% for normal hearing animals (regardless 
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of whether they were transfected with neurogenin or not), but 58% for the animals deafened with 
neomycin.  TuJ1 expression was only observed in 30% of the neomycin-deafened animals.  
These injected cells had been transfected with neurogenin and all expressed TuJ1.  None of the 
NSCs (even those transfected with neurogenin) in normal hearing hosts co-labeled for TuJ1.  For 
all experiments the actual number of surviving NSCs was typically low (at 2 weeks ~ 0.5%) with 
no significant differences between groups. 
 Kojima et al (2004) injected cells from the developing rat embryonic otocyst (day E12) 
into postnatal rats that had been exposed to damaging levels of noise (1 kHz – 20 kHz white 
noise at 120 dB SPL for 1 hour).  This damage caused more grafting of the IESCs into the 
cochlea as integration occurred in 3/8 of damaged hosts vs. 1/8 of undamaged hosts.  These data 
show that damaging the host was not required for cell integration, but it did help.  However, it is 
possible that all damage was due to the mechanical damage from the injection—not from the 
noise exposure.  No ABRs were performed to confirm the extent of hearing loss caused by the 
acoustic over-stimulation.  Even if the noise resulted in merely a temporary threshold shift, some 
trophic factors in the local environment may still assist stem cells integration and differentiation.  
By this same reasoning, a more-damaging, permanent loss could yield more-successful grafting.  
 In our experiments, the otocyst was only minimally damaged by the disruption of the 
developing sensory epithelium with the micropipette used for injections.  
In vivo injection 
 There are many ways to deliver therapeutic agents to the inner ear including: installation 
of an osmotic pump (useful for delivery of pharmaceuticals), creation of a niche at the round 
window (for drug delivery only to the basal end), and transection of the modiolus (to engraft 
neural cell tissue).  Sekiya et al (2006) even tried grafting ESCs into the internal auditory meatus 
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of damaged rat inner ears.  The ESCs migrated along the vestibulo-cochlear nerve to integrate 
into Rosenthal’s canal near the scala media and spiral ganglia.  They expressed β III tubulin and 
changed morphology, suggesting neural differentiation.  In addition, this injection caused 
minimal trauma and maintained the endolymph and perilymph compartments in the inner ear.     
 Most in vivo manipulations involve injections that disrupt the membranes of the inner ear 
in order to deliver stem cells or viral vectors for gene therapy.  Generally these methods result in 
donor cell aggregation around the injection site with only a few cells migrating or extending 
processes away from the injection site.  The differentiation of these cells may be limited by 
location because injected cells are not subjected to an array of environmental factors—only to 
what is nearby.  In our experiment, we injected cells into the developing chick otocyst.  In this 
model, cells are injected into the unstructured common lumen of the otocyst and have the ability 
to diffuse/migrate throughout the entire developing inner ear.  Unlike the adult model, injected 
cell survival and differentiation are likely to be affected by numerous factors in the surrounding 
embryonic environment.       
 
Methods
All procedures were performed in accordance with institutional board ethical guidelines for use 
of experimental animals.  
Egg Preparation 
 Fertilized White Leghorn chicken eggs were maintained at 4˚C for no more than 7 days 
before being placed in an automatic, rotating incubator at 37˚C at approximately 60% humidity 
(Day E0).  At day E3, eggs were removed from the incubator carefully so as to maintain embryo 
orientation.  Using an 18 gauge needle, 3 mL albumen was withdrawn from the egg.  A larger 
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window was slowly cut out of the shell using scissors.  Care was taken to allow time for the 
embryo to drop away from the shell if it had adhered.  Any embryos that did attach to the shell 
were discarded. 
 At this point, the developmental stage of the embryo was estimated by visualization of 
morphological features under a Leica MZ6 dissecting microscope.  Development of the otocyst, 
amnion, and overall embryonic features were compared to Hamburger and Hamilton’s atlas 
(1951) for staging of the embryo.  Using a 23 gauge needle the outer, chorion membrane that 
surrounds the amniotic sac and yolk sac was punctured so that a few drops of PBS could be 
injected for clearer visualization and manipulation of the embryo.  The entire chorion was then 
pulled away.  Using a tungsten needle, the amnion was removed exposing the otocyst. 
Stem Cell Cultures 
 Whole mouse bone marrow was collected from the tibias and femurs of an adult mouse 
by flushing the shaft with filter sterilized PBS.  The sample was placed in a cold centrifuge for 
five minutes and re-suspended in 20 μL DMEM until injection.  Cultured mouse bone marrow 
stem cells were obtained in the same manner but were plated out on media until confluent for 
three passages.  Remaining cells were assumed to be marrow stromal stem cells.  Adipose stem 
cells were obtained from the omentum of an adult mouse.  Cells were purified in culture and then 
were transfected with a neuronal specific Thy-1 promoter.  The promoter controlled the 
expression of green fluorescent protein (GFP) and Math-1 or neurogenin genes.  These ASCs 
cells were also enriched with undefined, intracellular hair cell proteins.  After 5 passages, cells 
were expanded in vitro.  At the time of injection, cultured cells were trypsinized, centrifuged, 




Stem Cell Injection 
Fast green dye was added to the suspension fluid to aid in visualization under the dissecting 
microscope.  Cells were loaded into a Nanoliter 2000 micropipette (World Precision 
Instruments), and approximately, 500 - 5,000 cells were injected into each exposed otocyst.  The 
eggs were then covered with tape and placed in a non-rotating incubator at 37˚C for 1 - 4 days. 
Dissection 
 At days E4 - E7 embryos were removed from the incubator and survival was verified by 
visualization of the heart beat.  The vitelline was punctured in two places and the embryo was 
removed from the egg using a forceps and spatula.  Embryos were placed in a dish of M199 
solution, and any remaining amnion membrane was removed with forceps.  Both otocysts were 
visualized.  For the three omental cell experiments, any injected cells expressing GFP were 
visualized at this time with inverted phase contrast and epifluorescent microscopy (Nikon 
TE2000-S).  To dissect out the otic region in all embryos, two cuts were made: one just rostral to 
the superior edge of the otocyst to free the head and another caudal to the inferior edge of the 
otocyst to free the tail. 
 Dissected otic regions were fixed in 4% Para formaldehyde to fix for 30 minutes to 1 
hour—depending on embryo size and age.  Following fixation, dissections were washed with 
PBS and placed in 30% sucrose (a cryoprotectant) overnight at 4˚C. 
 The following day, dissections were positioned in 10mm x 10mm x 5mm tissue tek wells 
filled with OCT.  To insure consistent orientation during cryostat sectioning, the left side of 
embryo faced up, the dorsal side was on the left, and the caudal side was on top.  The well was 
frozen into a block of OCT using a bath of dry ice and 2-methylbutane.  Specimens were 




Tissues were sectioned in the coronal plane from caudal end to rostral end in 10μm slices using a 
cryostat (Microm hm505N or 505E) kept at -20˚C.  Sections were mounted on slides that had 
been coated with chromium aluminum and were placed in a -80˚C freezer until 
immunohistochemical processing. 
Immunohistochemistry 
 First, non-specific binding of secondary antibodies was blocked with 1.0% BSA in 
Normal Goat and Normal Horse sera in PBS with Triton X-100 for two hours.  Tissues were 
reacted with primary antibody at 4˚C for 1 - 3 days, rinsed with PBS, and then placed in 
secondary antibody for one hour.  After rinsing with PBS, sections were double stained using 
streptavidin (Alexa 488) for biotinylated IgG diluted 1:500 in PBS for one hour.  This step was 
deleted for the three experiments using GFP labeled cells.  Next, all specimens were rinsed with 
PBS again and were stained with nuclear marker bis-benzimide diluted 1:1000 in PBS for 30 
minutes.  After a final PBS rinsing, sections were coverslipped in 90% glycerol in PBS.  All 
mounted sections were stored in 4˚C until viewing. 
 Primary antibodies included a rabbit polyclonal anti-calretinin antibody diluted 1:1000 in 
PBS; a rabbit polyclonal anti-β III Tubulin antibody diluted 1:1000 in PBS; a rabbit polyclonal 
anti-myosin VI antibody diluted 1:200 in PBS; a mouse polyclonal anti-β III tubulin (TuJ1) 
antibody diluted 1:500 in PBS; a mouse polyclonal anti-CD29 antibody diluted 1:100 in PBS; a 
rat polyclonal anti-CD34 antibody diluted 1:200 in PBS.  Secondary antibodies were CY3 anti-
rabbit diluted 1:500 in PBS and Biotinylated IgG anti-mouse or anti-rat diluted 1:130 in PBS. 
 Specimens were examined using a Nikon TE2000-S inverted epifluorescence microscope 
using 20, 40, and 100X objectives and were recorded using a side-mounted Q-Imaging Retiga 
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1300 camera.  Colorized processing of images was performed using Image Pro imaging 
software. 
 
Results and Discussion 
Donor Stem Cells and Pre-treatment 
 Five experiments were performed using the protocol stated above.  First, whole mouse 
bone marrow (directly from the donor without purification) was injected into 8 embryos (Einj 
9.14).  This cell source has an unknown composition of many cell types.  Many of these cells 
(i.e. erythrocytes) are known to die off, but remaining hematopoietic stem cells (HSCs) and 
marrow stromal stem cells (MSCs) may continue to live and possibly integrate (Ortiz-Gonzalez 
2004).   
 Cultured mouse bone marrow was utilized in the second experiment (MBM 10.26).  By 
culturing the whole bone marrow, only adherent cells were used for injection into 8 embryos.  
These cells were assumed to be MSCs by their morphology and self–renewing abilities. 
 Finally, a series of three experiments were performed using ASCs from the adult mouse 
omentum.  First, all purified ASCs were transfected with intracellular proteins from a line of hair 
cells.  Then, the cells were transfected with neurogenin and GFP (~80% transfection rate, Ngn 
2.20) or with Math-1 and GFP (2 experiments: ~ 10% transfection, Math-1 2.20; ~ 50 % 
transfection Math-1 3.6).  In comparing two day E4 specimens—one from each Math-1/GFP 
experiment, it is evident that the injection with a reportedly higher rate of transfection resulted in 
embryos with more GFP-labeled cells than the injection with Math-1/GFP cells with a reportedly 
lower rate of transfection (Figure 1).  Seven embryos were injected with neurogenin/GFP-
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transfected cells, and a total of 15 embryos were injected with Math-1/GFP transfected cells (6 - 
low transfection rate, 9 - high transfection rate). 
Host Animals and Pre-treatment 
 Despite the clinically relevant and successful use of mammalian host animals, we chose 
to use embryonic chicks for the following reasons.  First of all, chick development is well 
categorized and of short duration.  An extensive atlas is available from Hamburger and Hamilton 
(1951), and developmental stages of the chick inner ear are described by Knowlton (1967).  
Also, the developing chick inner ear is easily accessible for experimentation.  Eggs can be 
opened and re-sealed for experimentation—exposing the otocyst region without compromising 
the embryo.  In addition, the inductive interactions leading to cell differentiation in the chick are 
similar to those in mammals, allowing mammalian, injected cells to respond to avian 
environmental cues for development (Goldstein et al 2002).  Finally, existing protocols for use of 
chicks were readily available in our lab. 
 As already mentioned, many studies have shown that stem cells integration and 
differentiation can be made more effective with pre-injection ototoxic, noise induced, or 
mechanical damage.  Since the egg is a protected environment for the developing chick, pre-
treatment of the embryo with intentional damage may not have long-lasting effects on the local 
environment.  If damage is too severe, the embryo may not survive or the structures may heal on 
their own without incorporating the stem cells at all. 
 Our injection protocol caused only minimal mechanical damage at the site of the 
micropipette injection into the otocyst where the pars superior epithelium was punctured.  Also, 
more damage may have occurred by the injection of the additional volume of cells and 
suspension fluid into the confined otocyst.  With embryo #1 in the Math-1 3.6 experiment, an 
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intentional attempt was made to induce more mechanical damage with the pipette during the 
injection by repeatedly poking the otocyst epithelia.  Figure 2 compares this embryo to another 
embryo also at day E6 (#3 Math-1 3.6) with a more typical injection-induced damage.  There 
were no differences in the appearance of the host structures or in the properties of the injected 
cells regardless of degree of damage.   
 In all experiments, injected cells either remained near the injection site along the lateral 
wall of the otocyst, or they migrated to three locations: dorso-laterally to the developing superior 
sinus, ventro-medially to the junction of the developing endolymphatic and cochlear ducts, or 
dorsally up into the endolymphatic duct.  Since cells were found in other places besides the 
injection area—regardless of stage of development or extent of damage, it can be concluded 
from this study that any environmental factors released during damage do not play a role in stem 
cell migration by preferentially recruiting injected cells to the site of lesion.  However, with only 
one embryo as an example of more extensive damage and without any damaged control animals, 
this conclusion may be faulty.  Also, due to poor sectioning and processing, rarely was a 
complete otocyst fully sectioned, and never were all sections able to be photographed for any 
embryo.  It is possible that injected cells may have migrated to several other locations not shown 
in these limited data. 
In vivo injection 
 All injections took place on day E3 (approximately 72 - 78 hours after beginning 
incubation).  After opening the shell and peeling away the chorion and amnion membranes, the 
embryo’s stage of development was determined.  According to Hamburger and Hamilton (1951) 
and Knowlton (1967), embryos at day 3 should be at stages 19 - 23.  These authors admit that 
classifying embryos by chronological timing is flawed due to variability; hence they proposed a 
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morphologically based staging system.  Bissonnette and Fekete (1996) also observed variability 
in development as embryos were staged one half day behind normal development.  This delay 
can be attributed to prolonged onset of incubation of already fertilized eggs.  In our experiments, 
embryos ranged from stage 14 (presence of otic cup) through stage 18+ (heavy vascularization 
around otocyst).  Younger embryos where the otic cup was still open (such as embryo #4 Einj 
9.14) were injected with cells into the neural tube and into the medial mesenchyme in addition to 
into the developing otocyst (Figure 3).     
Despite any developmental delays, all embryos had to at least progress to Hamburger and 
Hamilton’s (1951) stage 12 (approximately day E2) to undergo the injections.  Embryos at this 
stage have begun to turn to the right side, exposing the right otocyst for injections.  The 
undisturbed left side served as a control.  In our experiments, two of the 38 embryos had turned 
to the left.  In these cases, the left otocyst was injected and the right side served as a control. 
 Survival of embryos was typical of previous chick manipulations in this lab and similar to 
other studies (Sakamoto et al 2004).  In each round of injections, approximately 2 - 4 embryos 
adhered to the shell and could not be injected.  Sometimes, the injection resulted in minimal 
embryo trauma, such as small extra-embryonic bleeds in the vitelline (N=7), larger extra-
embryonic bleeds (N=2), and carotid bleeds into the otocyst (N=2).  These injuries were not 
always detrimental to survival as only 3 of the 11 deaths (post-injection) were attributable to 
bleeds.  Of the total 38 embryos that were injected, 11 (28.9%) died before the otocyst could be 
dissected out for processing. 
 In each experiment, cells rested in the micropipette without agitation from the injection of 
the first embryo to the injection of the last embryo, totaling approximately 4 – 6 hours.  Over this 
time period cells began to coagulate—especially during the Math-1 3.6 study.  In this case, cells 
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were re-trypsinized before injection for the last two embryos in this experiment.  These embryos 
died before dissection and could not be examined further.  Cell clumping had two effects.  First, 
cells were injected as a large ball or mass of cells.  This could prevent interactions of these cells 
with environmental factors or integration into the epithelium.  Another disadvantage to clumping 
was that fewer cells were actually injected among the majority of suspension media.  Because of 
this, some embryos had few injected cells—if any—in the otocyst region.  However, a lack of 
cells in the lumen may also be attributable to an unlikely, complete integration of injected cells 
without detection, or more likely to faulty injections blocked by any remaining amnion covering 
the otocyst. 
Dissection of otic region 
 Prior to otocyst dissection, whole embryos could be viewed with inverted phase contrast 
and epifluorescent microscopy to visualize the efficacy of injections for the three ASC studies 
(Ngn 2.20, Math-1 2.20, Math-1 3.6).  In both Math-1 experiments, GFP-expressing cells were 
seen in the otocyst—sometimes only as a green blur (Figure 4).  Visualization became more 
difficult as density of the embryo increased with age.  At this stage, the neurogenin/GFP 
experiment did not show any cells clearly expressing GFP; only a minimal green blur was visible 
in one embryo.  After sectioning and before immuno-processing, these sections were checked 
again for GFP expression.  No sections from the neurogenin experiment expressed GFP; 
therefore, no further processing was completed.  Neurogenin is not normally found in epithelial 
cells.  Perhaps, the transfected cells had difficulty existing in the lumen of the inner ear and died 
early. 
 In all experiments, at least one embryo was dissected at days E4 and E5.  Embryos were 
dissected at day E6 in the cultured MSC study (MBM 10.26) and in all of the ASC studies—with 
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the exception of the Math-1 2.20 experiment.  A total of two embryos were incubated up to day 
E7 and survived—both from the Math-1 3.6 experiment.  In the whole mouse bone marrow 
experiment (Einj 9.14), embryo #8 survived until E8.  No further processing was completed due 
to time constraints. 
 All embryos were sectioned caudal to rostral except for embryo #5 from the Einj 9.14 
whole bone marrow study.  It had been positioned incorrectly in the OCT and all images should 
be reversed. 
Immunohistochemistry 
The Whole Mouse Bone Marrow injection experiment (Einj 9.14) had minimal results.  As this 
was the first experiment, injection and immuno-processing errors left few intact sections to be 
examined.  The sections that could be visualized show that injected cells do survive at least until 
day E5 (2 days post-injection).  Injected cells were present in the otocyst lumen at days E4 and 
E5; however differential staining of chick versus mouse cells with bis-benzimide was difficult to 
determine.  All injected cells were CD34 and calretinin negative and some were positive for 
TuJ1.   
At day E4, all injected cells were located near the injection site and some lateralized 
along the epithelium (Figure 5A).  It is unclear from the bis-benzimide staining as to whether any 
of the injected cells actually integrated into the chick otocyst epithelium.  Furthermore, if any 
injected cells did integrate, it cannot be determined whether they are part of the group of cells 
expressing calretinin.  These cells may have transdifferentiated into calretinin-positive cells by 
receiving environmental cues from the neighboring chick epithelial cells.  Whether the injected 
cells had integrated or not, it is possible that the intense calretinin expression in the epithelium 
could be due to the presence and activity of the injected mouse cells.  For reasons not fully 
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understood, the calretinin antibody used in our lab consistently labels this area of the common 
crus in this banding pattern at day E4.  As no sensory cells ever develop in this region (Knowlton 
1967) and since a complete comparison to the left control side is not possible, no clear 
conclusions can be made with these data.   
At day E5, injected cells were located in the otocyst lumen and near calretinin-positive 
sensory patches (Figure 5B).  Again, if these cells integrated and whether they express calretinin 
cannot be determined from these data.  The influence of the injected cells on the surrounding 
epithelium is also unknown because chick cells normally express calretinin in this area of the 
developing lateral semicircular canal.  It is clear that no local environmental cues from the chick 
caused any of the injected cells in the lumen to express calretinin.   
The difficulty in distinguishing between donor and host cells using bis-benzimide has 
also been cited in the literature.  Studies by Fontaine-Pérus (1995, 1997) also used differential 
bis-benzimide staining to distinguish between the chick and mouse cells.  According to these 
authors, chromatin of chick nuclei is more dispersed than the nuclear chromatin of the mouse.  
Because of the more condensed chromatin network, mouse cells will fluoresce brighter than 
chick cells.  These authors state that the difference in nuclear staining with bis-benzimide is less 
between mouse and chick than it is between quail and chick; and therefore, it can be difficult to 
assess which cells belong to which animal.     
Cultured Mouse Bone Marrow experiments (MBM 10.26) involved culturing of whole bone 
marrow to isolate the MSCs for injection.  No injected cells were identified in day E6 specimens.  
In a day E5 embryo (#6), injected cells were identified with bis-benzimide staining in the medial 
end of the developing cochlear duct.  All of these cells were CD34 and calretinin negative 
(Figure 6A and 6B).  The absence of CD34 labeling indicates that no HSCs were part of this 
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stem cell group.  By culturing the bone marrow, only CD34 negative MSCs that adhered to the 
culture plate were injected.  None of the cells labeled for calretinin; perhaps other markers like 
TuJ1 or GFAP would have labeled the MSCs.  This is one of only two examples from all 
experiments where injected cells were found in the region of the cochlear duct.  The other 
example was another day E5 embryo from the Math-1 2.20 experiment, embryo #6 (Figure 6C).  
In these cases, as before, it is difficult to determine injected cell integration into the epithelium 
due to poor visualization of differential bis-benzimide staining.  Also, it is possible that more 
embryos had injected cells in the area of the developing cochlear duct; but due to poor 
processing, few slides were intact enough to be viewed. 
 In general, the injections of the MSCs were not successful due to a small volume of cells 
available for injection and experimental errors injection and processing.  Other authors have 
demonstrated neural-differentiation in vivo with this type of cells (ear-Naito et al (2004), brain-
Zhao et al (2002), eye-Kicic et al (2003), and spinal cord-Pochampally et al (2004)).  These 
experiments used damaged adult hosts injected with enriched MSCs.  Results indicated that 
injected cells migrated to sites of neural damage and expressed appropriate neural markers; 
therefore another attempt of this model is worthwhile.  Modifications would include: obtain more 
cells through more cultures, use a more reliable GFP marker for easier injected cell 
identification, and prolong the amount of incubation time post-injection prior to dissection. 
Three experiments using cells from the Omentum (Math-1 2.20, NGN 2.20, and Math-1 3.6) used 
transfected, purified ASCs for injection.  With both of the bone marrow experiments, it was 
difficult to distinguish between mouse and chick cells in the epithelial region.  To aid in 
determining whether the injected omental cells did integrate into the host epithelium, the next 
three experiments used green fluorescence to mark the injected cells.  Results of the neurogenin 
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experiment were discussed earlier (Results: Dissection of otic region) and are not discussed 
further in this section. 
 Two experiments were performed with ASCs transfected with Math-1/GFP.  They varied 
in success of gene transfection into the donor cells (Figure 1).  The experiment performed on 
2.20 not only had a low rate of Math-1/GFP transfection, but also a low experimental yield as 
only three embryos survived to dissection.  When viewed prior to dissection, only two of these 
embryos had any GFP expression.  Once fully processed, all three embryos did show successful 
cell injections.  Due to the low Math-1/GFP transfection rate in this example, screening embryos 
for GFP post-injection prior to processing did not reflect failure or success of the injection.  It 
was only indicative of the presence or the absence of GFP-expressing cells.  Screening embryos 
prior to the extensive sectioning and immuno-processing was a useful tool to identify the Math-
1/GFP cells that are of the most interest. 
All three embryos were sectioned and processed.  The two day E4 embryos had bis-
benzimide positive cells in the lumen of the developing otocyst.  Embryo #1 did show some 
GFP-expressing cells that were negative for myosin VI (Figure 1A).  Embryo #3 also had some 
GFP-expressing cells prior to dissection; however, due to poor processing resulting in few intact 
sections, none of the available data show any GFP-expressing cells after immuno-processing.  
None of the injected cells expressed myosin VI (Figure 7A & 7B).  At day E5, only one embryo 
had survived to dissection (embryo #6), but this embryo did not have any GFP-expressing cells 
when viewed prior to dissection.  Once completely processed, this embryo did have injected cells 
located in the lumen of the otocyst.  The available sections are from the most caudal end of the 
otocyst, and bis-benzimide staining in the otocyst lumen may in fact be the wall of the otocyst 
(Figure 8).  In injected cells in this area all express CD29, a mesenchymal cell marker, and some 
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of these cells label for GFP/Math-1 too (Figure 9).  The morphology of these cells cannot be 
determined from these data; but expression of both markers indicates that the ASCs have not 
fully-differentiated yet.  As these cells continue to express CD29, they may become 
mesenchymal cells.  A few examples of injected mesenchymal stem cells maintaining their 
mesoderm fate can be found in the published literature: Castro et al (2002) and Massengale et al 
(2005).   
Another section of this embryo did show a GFP-like green haze in the cochlear duct that 
was not present on the opposite (Left control) side (Figure 10B & 10C).  There was no co-
labeling with bis-benzimide for this section in this area indicating an absence of cellular nuclei in 
the lumen.  However in a preceding section (Figure 10A), non-GFP-expressing nuclei are located 
in the ventro-medial cochlear duct.  Perhaps, the green haze is a remnant left behind by GFP-
expressing, injected cells that died by this stage, leaving only non-GFP-expressing cells in the 
lumen.   
 From the second Math-1/GFP experiment performed on 3.6, many more sections are 
available for data as 7 out of 9 injected embryos survived until dissection.  Also, by this time 
experimental error decreased due to acquired skills in sectioning and processing.  One embryo 
was dissected at day E4.  In this specimen, injected cells were labeled with GFP and bis-
benzimide, but none were labeled with calretinin.  The red staining visible in the mass of cells 
does not co-label with bis-benzimide.  Therefore, there was no true calretinin expression by any 
injected cells—only dead cell remnants without nuclei that auto-fluoresce (Figure 1B).  In more 
rostral sections, the mass of cells invaded the developing endolymphatic duct.  In the most 
caudal sections, the neighboring chick epithelium expressed calretinin in a similar way to what 
was seen in the whole bone marrow injections (Figure 5A).  The calretinin labeling was on the 
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dorsal edge of the otocyst (Figure 11A).  Additional imaging of the left side of this embryo 
(Figure 11B), illustrates that calretinin expression in this region is normal at this stage—but it is 
not as intense as on the affected side.  These findings suggest that the mass of GFP/Math-1-
expressing cells can have some effect on the surrounding chick epithelium, resulting in an 
increase in calretinin expression.  Unlike with the previous two experiments, here it is clear that 
the injected cells are not in the group of calretinin-expressing cells in the host membrane because 
all of these cells are GFP negative.   However, as green fluorescence only indicates the 
transcription of the plasmid containing GFP and Math-1, it does not indicate the location of the 
Math-1 protein once made by the injected cells.  Therefore, it is still possible that Math-1 (or 
another agent) was secreted by the injected cells to increase calretinin expression in the host 
cells. 
 Two embryos were dissected at day E5.  In both cases, there were fewer GFP-expressing 
cells present than in day E4 embryos.  In fact, there were fewer injected cells overall.  Results 
show migration of the GFP-expressing cells up into the endolymphatic duct (Figure 12).  There 
was little evidence of injected cells anywhere else in the developing inner ear.  Most likely, many 
of the injected cells have died off at this point post-injection, or perhaps fewer cells were injected 
into this embryo due to the clumping discussed earlier.   
As before, all injected cells were calretinin negative; but in contrast, all cells of the 
neighboring epithelium of the endolymphatic duct were also calretinin negative.  These results 
indicate that the injected cells had no detectable effect on the host cells.  Since the host cells in 
this area would normally never express calretinin at any point in their development, perhaps they 
are not responsive to Math-1.  GFP expression is very strong in these cells.  It can be assumed 
that Math-1 is strongly expressed as well.  Since the injected cells themselves do not express 
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calretinin at this point in development, perhaps more time is needed for these cells to 
transdifferentiate and label for the mature sensory cell calcium channel protein, calretinin.  Even 
though sensory patches were staining calretinin positive in other appropriate areas of the chick, it 
is possible that the transdifferentiating ASCs may have a delay in their development as compared 
to the typically developing host cells.  Staining with an earlier neural progenitor marker, like 
nestin, might be helpful at this stage.   
 At day E6, two embryos were dissected.  In both specimens, GFP was expressed in some 
of the injected cells located in the lumen of the otocyst.  None of the injected cells expressed 
calretinin.  These two embryos have been discussed previously in the section on damage to the 
host epithelium (Host Animals and Pre-treatment).  Figure 2 shows the location of the injected 
cells in these embryos.  The large cell mass in embryo #1 (A) was typical throughout this 
experiment; however, embryo #3 (B) warrants further discussion.  In the most dorsal edge of the 
superior sinus, some GFP-expressing cells appeared to be arranged in line with other cells in the 
host epithelium.  Upon further examination of each filter color channel, it is clear that all of the 
injected cells have not integrated into the epithelium, but are merely part of the mass of cells 
(Figure 13).  Previous and subsequent sections of this area confirm that no injected cells 
integrated into the epithelium. 
 At day E7, two embryos were dissected and processed; however embryo #4 contained no 
GFP-expressing cells.  The efficacy of the injection into this embryo was questionable at the time 
of injection, but processing was completed for verification.  Embryo #7 had a limited number of 
cells expressing GFP when checked prior to dissection and also once fully processed.  Unlike all 
other experiments, the GFP-expressing injected cells crossed the epithelial barrier and were 
integrated into the host mesenchyme along the ventro-medial edge of the endolymphatic duct at 
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day E7 (Figure 14).  As there were no bis-benzimide labeled cells in the lumen, all non-
integrated cells had died by this point.  In other embryos at day E5, cells were found in the lumen 
of the endolymphatic duct.  Embryo #7 must have also had cells tucked into that space on 
previous days too.  By day E7, injected cells had integrated into the mesenchyme adjacent to 
where the injected cells had been in day E5 specimens. 
 The morphology of the GFP-expressing cells had also changed (Figure 15A).  The cell 
bodies were globular, and they had processes extending in a bipolar fashion—indicating 
differentiation into a neural cell type.  This was confirmed by calretinin labeling; all of the 
GFP/Math-1-expressing cells co-labeled for calretinin (Figure 15B).  Some additional calretinin 
staining in the region did not co-label for bis-benzimide, and therefore it was probably a result of 
the autofluorescence of dead, injected cell remnants (Figure 15C).  None of the host cells labeled 
with calretinin; and therefore, they must not have received any signals from the injected cells.  In 
this area of the inner ear, no cells would express calretinin at any point in normal development.  
Despite the common lineage of the injected cells and neighboring cells of the mesenchyme, the 
injected ASCs transdifferentiated into neural cells and did not continue along a mesenchymal 
cell lineage.  This could be attributed to Math-1 expression encouraging these cells to adopt a 
neural cell fate.  However, Math-1 expression was not enough to encourage these cells to adopt a 
hair cell fate.  In development, Math-1 usually acts once cells leave the cell cycle and after they 
have become neural progenitors.  The time window for Math-1 to influence the injected cells 
may have passed in our specimens.  Expression of Math-1 may decrease over time as these cells 
have not adopted epithelial cell morphology and will not become hair cells.  Other studies 
confirm these findings.  Mesenchymal stem cells have differentiated into neurons, but not hair 




 As discussed earlier, several researchers have illustrated the capacity of mesenchymal 
stem cells to transdifferentiate along a neural path, but perhaps with only limited ability: few 
become neurons, whereas a majority of cells become glial supporting cells.   
From all of our experiments with all types of mesenchymal stem cells, only a few 
examples of differentiation and integration were obtained.  Therefore, these injected 
mesenchymal stem cells cannot be completely characterized.  Most of the mass of cells, labeled 
only for the nuclear stain, bis-benzimide; other dead cell remnants merely autofluoresced.  In the 
first experiment with whole bone marrow, some cells labeled for TuJ1; but none of the ASCs 
labeled for β III tubulin.  In the final ASC experiments, many cells labeled for Math-1 
expression, but only a few co-labeled with calretinin and none labeled for myosin VI.  In 
addition, some injected cells continued to label with mesenchymal cell marker CD29.  As our 
data in these experiments was very limited, one cannot conclude the true phenotype of these 
injected mesenchymal stem cells.     
That being said, our data suggest that mesenchymal stem cells have a very limited ability 
to transdifferentiate into neural cells in vivo.  These cells only expressed calretinin in the one 
case of integration.  With calretinin expression and the change in morphology, it is likely that 
these cells are beginning to differentiate into neural cells.  It can be concluded that—even with 
Math-1 expression—stem cells derived from the mesenchyme cannot transdifferentiate into hair 
cells when injected into the developing otocyst of the chick; but they may begin to integrate and 
differentiate into neurons by day E7.  
In order for injected cells to become useful for functional recovery, they must either 
integrate into the sensory epithelium as a hair cell or into the area of the developing vestibulo-
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cochlear ganglia.  Our results did not identify any integrated stem cells in either of these areas.  If 
injected cells survived long enough to integrate, they did so into the mesenchyme surrounding 
non-sensory areas of the inner ear instead. 
 
Future directions would include modifications of the stem cell sources, the host animals, and the 
immuno-processing.  First, to ease injection, stem cell clumping should be minimalized.  Also, 
the properties of the omentum-derived enriched cells need to be further defined in vitro.  The 
transplanted hair cell proteins and their effects on the stem cells require further characterization 
too.  In addition, other stem cell sources could be tried.  Preliminary injections of IESCs from the 
supporting cell layer of the quail utricle have been attempted.  Perhaps these cells will be easily 
induced into a hair cell fate as they have been known to do in non-mammalian hair cell 
regeneration.   
 Modifications could also be made to the host.  As opposed to the highly inductive and 
nurturing environment of the normally developing chick inner ear, better stem cell integration 
and differentiation may be demonstrated in a more clinically analogous paradigm such as adult 
mammals with acquired hearing loss or postnatal mammals with congenital hearing loss.  If 
chick embryos are used, more injections should be done to control for experimental variables.  In 
our study, the left side served as a control for each animal.  The addition of normally developing 
controls could help to determine the normal expression of different cellular markers for 
comparison.  Embryos injected with a mock solution could show the effects of the injection in 
damaging the epithelium.  And finally, more embryos should be dissected at older stages.  As 
integration was finally seen at day E7 with these experiments, further study utilizing longer post-
injection incubation periods (E8 or E9) is warranted.  By waiting until the chick has reached 
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near-adulthood, more integration and further differentiation of injected stem cells could be 
characterized.  Furthermore, a more well-defined damage protocol using an aminoglycoside 
could be used.   
 Other improvements could be introduced to better characterize the phenotypes of the 
injected stem cells.  As few of our embryos survived 4 days post-injection, it would be 
worthwhile to label with a neural progenitor cell marker that can detect the intermediate stages of 
stem cell differentiation at the earlier embryonic stages.  As normal hair cell differentiation 
(visible with calretinin and myosin VI labeling) is limited to day E6 - E12, it may be difficult to 
determine hair cell phenotype in early embryos.  To better define more-mature cells, supporting 
cell markers, glial cell markers, or other mesenchymal cell markers could be implemented too.   
Additional research is needed to determine what environmental cues play roles in the 
normal development of inner ear cell types and in the differentiation of injected stem cells.  Also, 
an ideal mechanism of cell delivery that preserves the intact structures of the host has yet to be 
determined.  Stem cells must preferentially migrate from the injection/engraftment site to the 
damaged areas within the inner ear.  And finally, these stem cells must prove effective in 
restoring hearing function in order to be implemented clinically.   
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Figure 1 GFP Transfection rate reported from culture was 
verified in vivo.
A: Section from a day E4 embryo with a low transfection 
rate had few cells expressing GFP.
B: Section from a day E4 embryo with a high transfection
rate had more GFP-expressing cells for a comparably-




Figure 2 Excessive damage during injection had no effect 
on the migration of injected cells.  
A: Section from a day E6 embryo with a mass of injected 
cells in a common location, near the junction of the 
developing cochlear and endolymphatic ducts—not near the 
site of damage along the dorso-lateral edge of the otocyst. 
B: Section from another day E6 embryo with more-typical
damage.  Injected cells had migrated to the dorso-lateral 
edge of the developing superior sinus.
Einj (9.14) E4
Calretinin/TUJ1
Figure 3 Whole mouse bone marrow injection results at day 
E4.  Embryo was injected at stage 14+.
A: Injected cells are in the lumen of both the otocyst and the 
neural tube.  Some express TuJ1, but only cells of the lateral 
epithelium of the otocyst express calretinin.
B: Image of same embryo.  Cells are not present in the control 
otocyst, but are in the neural tube.  Some injected cells 
express TuJ1, but none express calretinin. It is not possible to
visualize the entire control otocyst to verify calretinin 
expression normally occuring in the lateral otocyst region.
B
A
Figure 4 Views of GFP 
expression in day E4, 
E5, and E6 embryos 
prior to dissection.  
Visualization at this point 
served as a helpful 
intermediate step to 
identify unsuccessful 






Figure 5 Injected whole mouse bone marrow cells were 
present near calretinin-positive areas of the epithelium.
A: Section from a day E4 embryo with injected cells lined up 
along the lateral wall of the otocyst.  This section was not 
photographed for TuJ1 expression, but previous and 
subsequent slides do not show any TuJ1 expression in this 
area (40x). 
B: Section from a day E5 embryo with injected cells near the 
chick sensory patches of the developing lateral semicircular 










Figure 6 A (caudal) & B (rostral): Two sections from the 
same embryo illustrating that injected cells migrated down 
ventrally into the developing cochlear duct at day E5.  These 
cells label only with bis-benzimide for nuclei.
B
Figure 7 Results of two embryos at day E4 from the low 
transfection rate Math-1 experiment.
A: Injected cells survive in the otocyst one day post-injection, 
but do not express GFP or myosin VI.












Figure 8 Injected cells 
continue to express 
mesenchymal cell marker, 
CD29 at day E5.
A: GPF/Math-1 is 
expressed by most of the 
injected cells.
B: CD29 labels all injected 
cells in otocyst region. 
Some CD29 cells co-label 
for GFP.
C: CD29 cells have nuclei 
and label with bis-
benzimide. 












Figure 9 Injected cells 
continue to express 
mesenchymal cell marker, 
CD29 at day E5.
A: GPF/Math-1 is 
expressed by most of the 
injected cells.
B: CD29 labels all injected 
cells in otocyst region. 
C: Some CD29 cells co-
label for GFP.
D: Merge of GFP/Math-1,  










Figure 10 Results from Math-1/GFP 2.20 day E5 continued.
A. Injected cells migrated to the ventro-medial end of the 
cochlear duct, but do not express CD29 or GFP.
B. GFP expression in the developing cochlear duct did not 
co-label with bis-benzimide for the presence of nuclei. 
C. Left otocyst (control) confirmed that affected side results 





Figure 11 Injected cells were present near calretinin positive 
chick epithelial cells.
A: GFP expression of injected cells near developing 
endolymphatic duct induced more intense calretinin
expression in neighboring host cells.  
B: Left otocyst (control) confirmed that results from the 






Figure 12 GFP-expressing injected cells congregated in 
the lumen of the developing endolymphatic duct at day E5. 
Figure 13 Separate color 
channel images of day E6 
embryo showed no 
integration of GFP-
expressing injected cells 








Figure 14 GFP-expressing 
injected cells integrated into 
the host by Day E7.  
A: Section with injected 
cells located in the 
mesenchyme, ventro-
medial to the endolymphatic
duct—not in the lumen. 
B: Successive section 20x









Figure 15 Injected cells 
begin to differentiate by 
day E7.
A: GPF/Math-1 expressing 
cells adopt neural cell 
morphology 
B: Some GFP cells co-
label for calretinin.
C: Some calretinin staining 
does not co-label with bis-
benzimide.
D: Merge of all 3 color 
channels
GFP/Calret
Calret/bis-benz
A
B
C
D
